Hong Kong and Taiwan HM3 PMS
Launched by ABBOTT MEDICAL DEVICES · Jan 8, 2021
Trial Information
Current as of July 22, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - All patients at the participating sites that are determined to meet the HM3 commercially approved labelling indication and have a planned HM3 implant are eligible to participate in this PMS. Assessment for eligibility criteria is based on medical records of the site and interview with a candidate patient.
- • Exclusion Criteria: None
About Abbott Medical Devices
Abbott Medical Devices is a leading global healthcare company dedicated to advancing medical technology through innovative research and development. With a robust portfolio of diagnostic, therapeutic, and monitoring solutions, Abbott is committed to improving patient outcomes and enhancing the quality of care across various medical fields. The company places a strong emphasis on clinical trials to validate the safety and efficacy of its products, ensuring compliance with regulatory standards and fostering collaboration with healthcare professionals. By leveraging cutting-edge science and technology, Abbott Medical Devices aims to address pressing health challenges and deliver transformative solutions that empower patients and healthcare providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei City, , Taiwan
Taipei City, , Taiwan
Hong Kong, Pokfulam, Hong Kong
Patients applied
Trial Officials
Carlo Gazzola, B. Sc.
Study Director
Abbott Medical Devices
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials